Johnson & Johnson bets $1 billion on hard-to-treat cancer

Article excerpt

Johnson & Johnson is investing $1 billion to develop treatments for difficult-to-treat cancers, betting on a portfolio of experimental drugs designed to target tumors that have resisted conventional therapies. The pharmaceutical giant's move reflects intensifying competition in oncology, where companies are racing to capture market share in specialty treatments. The investment spans multiple therapeutic approaches, including immunotherapy and targeted molecular treatments. J&J's wager signals confidence in emerging science while acknowledging the commercial stakes in cancer care, where successful drugs command premium pricing.